Cyclin-Dependent Kinase Inhibitor 1B (CDKN1B) (C-Term) antibody

Antigen: Cyclin-Dependent Kinase Inhibitor 1B (CDKN1B)

Synonyms: KIP1, MEN4, CDKN4, MEN1B, P27KIP1, p27, Rpn4, MGC8644, Kip1, Cdki1b, sb:cb611, wu:fb63g10, wu:fb64g10, wu:fe18e03, CDKN1B

Binding Site: C-Term

Clonality: Polyclonal

Host: Rabbit

Reactivity: Please enquire

Conjugate: Un-conjugated

Application: Immunohistochemistry (IHC), Western Blotting (WB)

Catalog no.: ABIN350690

Additional Information

Alternative name: p27 Kip1

UniProt: P46527

Immunogen: A synthetic peptide from c-terminal region (~aa 100-170) of human p27 Kip1 (KIP1, p27Kip1) conjugated to an immunogenic carrier protein was used as the immunogen.

Format: Lyophilized

Isotype: IgG

Description: FUNCTION: Important regulator of cell cycle progrssion. Involved in G1 arrest. Potent inhibitor of cyclin E- and cyclin A-CDK2 complexes. Positive regulator of cyclin D-dependent kinases such as CDK4. Regulated by phosphorylation and degradation events. Decreased levels of p27Kip1, mainly due to proteosomal degradation, are found in various epithelial tumors originating from lung, breast, colon, ovary, esophagus, thyroid and prostate. SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note: Nuclear and cytoplasmic in quiescent cells. Tissue specificity: Expressed in all tissues tested. Highest levels in skeletal muscle, lowest in liver and kidney. Also known as: Cyclin-dependent kinase inhibitor 1B, Cyclin-dependent kinase inhibitor p27, CDKN1B, KIP1, p27Kip1, p27 Kip 1.

Specificity: Appears to be specific for p27Kip1.

Application Details

Application Notes: IHC, WB. A concentration of 10-50 µg/ml is recommended. The optimal concentration should be determined by the end user. Not tested in other applications.

Purity: IgG

Purification: Purified human T-Cells

Storage: Maintain the lyophilised/reconstituted antibodies frozen at -20°C for long term storage and refrigerated at 2-8°C for a shorter term. When reconstituting, glycerol (1:1) may be added for an additional stability. Avoid freeze and thaw cycles.

Restrictions: For Research Use only

Publications

Pietenpol, Bohlander, Sato et al.: "Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias." in: Cancer research, Vol. 55, Issue 6, pp. 1206-10, 1995 (PubMed).

Polyak, Lee, Erdjument-Bromage et al.: "Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals." in: Cell, Vol. 78, Issue 1, pp. 59-66, 1994 (PubMed).

Ishida, Kitagawa, Hatakeyama et al.: "Phosphorylation at serine 10, a major phosphorylation site of p27(Kip1), increases its protein stability." in: The Journal of biological chemistry, Vol. 275, Issue 33, pp. 25146-54, 2000 (PubMed).

Viglietto, Motti, Bruni et al.: "Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer." in: Nature medicine, Vol. 8, Issue 10, pp. 1136-44, 2002 (PubMed).

Grimmler, Wang, Mund et al.: "Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases." in: Cell, Vol. 128, Issue 2, pp. 269-80, 2007 (PubMed).